---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000004"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:09:19.741871+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arvinas updates Phase 3 vepdegestrant combo trials; VERITAC-2 topline data expected Q1 2025

## Summary
- Topline data for VERITAC-2 Phase 3 monotherapy trial of vepdegestrant expected in Q1 2025.
- First-line Phase 3 combo with Pfizer's atirmociclib planned for 2025; VERITAC-3 (palbociclib combo) discontinued.
- Phase 1 trial of ARV-102 (LRRK2 degrader) in Parkinson's disease initiated; data at AD/PD conference April 2025.
- Alex Santini appointed interim CCO effective Jan 17, 2025; John Northcott leaving for personal reasons.
- IND filing for KRAS G12D degrader and initial data from ARV-393 (BCL6 degrader) expected in 2025.

## SEC filing metadata
- accession: 0001655759-25-000004
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/0001655759-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000004/arvn-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000004
- JSON: https://secwatch.observer/filing/0001655759-25-000004.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.